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Abstract
Pharmaceutical disposal and the environmental fate of medication metabolites directly impacts the public’s health
in two significant ways: accidental medication ingestion of pharmaceuticals that were not disposed of properly
results in inadvertent toxicity; and environmental health consequences of pharmaceuticals that were inappropriately
disposed and which contaminate municipal water supply. In reviewing the effectiveness of medication disposal
policy globally, it is crucial to not only determine which policies are effective but also to assess why they are
effective. By assessing the root causes for a specific policy’s effectiveness it can be determined if those successes
could be translated to another country with a different health care system, unique culture and divergent policy
ecosystem. Any intervention regarding pharmaceutical disposal would require a multifaceted approach beyond
raising awareness and coordinating pharmaceutical disposal on a national level.
While consumer participation is important, effective primary prevention would also include research on drug
development that is designed to biodegrade in the environment as opposed to medications that persist and
accumulate in the natural environment even when properly disposed. Countries that lack a nationalized disposal
policy should leverage the resources and infrastructure already in place in the national health care system to
implement a unified policy to address medication disposal in the short-term. In tandem, efforts should be made to
recruit the biotechnology sector in high-tech and academia to develop new technologies in medication design
and water filtration to decrease exposures in the long-term.
Background
The matter of medication disposal has direct impact on
the public’s health in two significant ways: accidental
medication ingestion of pharmaceuticals that were not
disposed of properly resulting in inadvertent toxicity;
and environmental health consequences of pharmaceuti-
cals that were inappropriately disposed and which con-
taminate the municipal water supply. In a recent IJHPR
article, Barnett-Itzhaki and colleagues discuss the unique
challenges of inappropriate disposal of pharmaceuticals
in Israel due to the lack of any national policy or pro-
gram to address the issue. To this end, the authors re-
view national programs and policies throughout the
world (focusing on Europe and North America but also
noting programs in selected Middle Eastern countries)
and suggest possible policy directions for Israel [1].
Towards effective policy
In reviewing the effectiveness of medication disposal
policy globally, it is crucial to not only determine which
policies are effective, but also to assess why they are effect-
ive. By assessing the root causes for a specific policy’s
effectiveness it can be determined if those successes could
be translated to another country with a different health
care system, unique culture and divergent policy ecosys-
tem. The application of environmental public health
policies from one country to another can be met with
resistance and limited success. One such example is the
challenge of “harmonizing” pesticide legislation worldwide
when international trade organizations such as NAFTA
have attempted to apply established policies from devel-
oped countries to developing nations [2]. When Mexico
attempted to adopt US clean air laws in the 1990s, the
aging Mexican auto fleet lacked the catalytic converters
needed to run unleaded gasoline, resulting in a temporary
increase in emissions. Since “copy-paste” public health
policy can be inefficient at its best, and harmful at itsCorrespondence: eamster@post.harvard.edu
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worst, it is best to emulate the principles behind effective
policies rather than attempting to copy the policy itself.
This is exceedingly true when applied to the topic of
pharmaceutical waste in Israel. For example, regulations
in certain states in the United States and published
guidelines of the Poison Control Center recommend
flushing certain pharmaceuticals down the toilet [3]. In
Israel, a world-leader in water reclamation for agricul-
ture (see below), this would result in a significant in-
crease in pharmaceutical metabolite concentration in
produce. Conversely, a pharmacy-directed medication
return program such as the EnviRx program launched in
British Columbia in 1996 [4], may have even greater suc-
cess in Israel where most pharmacies are owned by the
HMOs as opposed to small private entities. Any
pharmaceutical disposal policy would need to be inte-
grated in the national healthcare system across the four
community based HMOs and governmental hospitals.
Disposal policies such as collection and destruction
systems ultimately are only as successful as the public’s
participation. As noted in Barnett-Itzhaki’s article, even
throughout the EU, which has implemented a number of
directives on the issue dating back to 2001, compliance
with disposal policies is at 50% [5]. Therefore, the imple-
mentation of disposal policies is an integral component
of compliance and eventual success. Health promotion
strategies such as consumer marketing and advertising
through traditional and new media has been effective in
public health campaigns in Israel and globally.
The authors note that lack of awareness among
consumers and physicians “regarding the health and en-
vironmental implications of medication accumulation
and disposal” is a significant barrier in the successful ap-
plication of any program [1]. While this is likely true,
awareness alone is not sufficient to motivate change in
individual health behavior. In applying the health belief
model [6], perceived severity, susceptibility, benefits and
barriers of inappropriate medication disposal would fac-
tor into the likelihood that consumers would participate
in disposal programs. Even if awareness of the issue is
addressed through social networks, publicity projects,
campaigns and brochures as the authors advise, per-
ceived health severity of inappropriate disposal and the
perceived personal benefit of disposal program participa-
tion would likely remain low. The integrated behavior
model suggests that behavior is determined by factors
beyond awareness and that intention is determined by
factors including norms and attitudes [7]. One of the
three methods for changing social health norms is by
making peer behavior visible and creating peer expecta-
tions [8]. Pharmaceutical disposal and participation in
disposal programs is not a visible peer behavior and
would be difficult to become a social norm through
awareness alone.
A multifaceted approach
Any intervention on this issue would require a multifa-
ceted approach beyond raising awareness and coordinat-
ing pharmaceutical disposal on a national level. An
assessment must be carried out on the natural fate of
medications through their lifespan from production to
disposal. This would answer the question of which medi-
cations are most likely to end up in the environment
and which prescriptions present the greatest public
health risk. This would enable a targeted abatement pro-
gram for specific classes of medications. Medications
that persist in the environment longer would also be
given higher priority in a targeted abatement program.
Healthcare providers and pharmacies can invest in pro-
grams for those specific medications such as automated
reminders to the pharmacist at the time of medication
renewal or requiring that the patient bring in the previ-
ous medication bottle or container at the time of refill.
Applications on mobile devices such as pill trackers can
be integrated into the care of patients with chronic
illness, as well as the care of those patients who are at
the highest risk of poly-pharmacy and inappropriate
medication disposal.
Surveillance of policy compliance should be carried
out regularly throughout the health system from mul-
tiple perspectives (HMOs, hospitals, pharmacies, con-
sumers) and across diverse sectors of the population.
Effectiveness of policy implementation should not only
be viewed in terms of consumer participation; down-
stream effects should also be followed. For example, a
natural benefit of improved medication disposal would
be the decline of accidental medication ingestion moni-
tored by the national poison control center, and de-
creased concentration of medication metabolites in
recycled water monitored by the Ministry of Environ-
mental Protection and local water authorities.
Designing more ecological pharmaceuticals
The above-mentioned interventions require the involve-
ment of multiple stake-holders and active participation
of the health care consumer. In contrast, truly effective
primary prevention would be passive and include re-
search on drug development that is designed to bio-
degrade in the environment as opposed to medications
that persist and accumulate in the natural environment
even when properly disposed. This would also address
the issue of medication metabolites that are excreted in
urine and feces and end up in sewage treatment plants,
facilities which are not designed to filter out medications
and their metabolites. The efficacy of filtration systems
varies with both the specific medication and the type of
purification process utilized at the sewage treatment
plant. Estimates vary from 65% reduction in medication
concentration to 0% for some medications such as
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psychoactive medications, which are not filtered by sew-
age treatment plants [9].
In a country such as Israel which reclaims up to 90%
of waste water for agricultural purposes [10], pharma-
ceutical waste products and metabolites inevitably end
up in the food supply. Grossberger and colleagues found
that certain medications such as carbamazepine, lamotri-
gine, caffeine, metoprolol, sulfamethoxazole and sildena-
fil persisted in agricultural soils irrigated with treated
wastewater [11]. This suggests that even the most suc-
cessful household medical waste disposal policy would
leave the issue of excreted pharmaceutical metabolites
unaddressed. In addition to addressing medication de-
sign, delivery and environmental fate, municipal sewage
treatment facilities, specifically in areas where pharma-
ceutical industries operate should be equipped to ad-
dress the growing issue of pharmaceuticals in the water
supply.
Addressing industrial pharmaceutical waste
As noted in Barnett-Itzhaki’s article, many governments
have modeled the “polluter pays” principle, although in
terms of household pharmaceutical waste it is unclear
who the “polluter” is. Is the pharmaceutical industry the
“polluter” or is it the health care consumer? And what
role does the pharmacy and provider play beyond advo-
cating awareness? Who is the responsible party? Ultim-
ately, it comes down to a question of “Who should fund
such programs?” These questions are difficult to answer
in terms of household pharmaceutical waste; however, in
terms of industrial pharmaceutical waste the question
(and the answer) is much clearer. If Israeli pharmaceut-
ical companies are sponsoring medication disposal pro-
grams in countries such as Mexico [12], it is reasonable
to expect that the 20 billion dollar Israeli pharmaceutical
industry will contribute to the development and imple-
mentation of programs in Israel.
In terms of quantity and potential public health im-
pact, industrial pharmaceutical waste is a much greater
issue than household pharmaceutical waste. Israeli
pharmaceutical companies are the leading producers of
generic medications in the world [13]. The quantity of
unused, disqualified, expired medications as well us pro-
duction by-product and residual that is discharged as in-
dustrial effluent is unreported, even though is likely to
be significant. The high concentrations of pharmaceut-
ical material discharged from factories far outpaces the
ability of the municipal water treatment facility’s ability
to treat wastewater when compared to the relatively low
concentration of metabolites disposed of and excreted
by the health care consumer. As industrial discharge of
pharmaceuticals involves a point source exposure, it is
easier to monitor and regulate than consumer disposal.
This would involve a different regulatory mechanism
than addressing household pharmaceutical waste and
would require leadership from the Ministry of Environ-
mental Protection on the matter.
Conclusions
In some regards, Israel and other countries with no
existing national policy or program for medication dis-
posal are at an advantage. There is no set precedent or
pretext that would limit innovation in designing novel
intervention. There are no ineffective policies or ineffi-
cient systems already in place tying up national re-
sources. There are no competing and at times
contradictory policies and programs in place as is the
case in the United States or Canada. Considering this
and the limited success of existing national policies in
other countries, countries with no current existing na-
tional policy should not rush to copy inefficient existing
programs but rather should design tailor =made pro-
grams and implement policies that are appropriate to
their unique health care system and public. Israel should
leverage the resources and infrastructure already in place
in the community based HMOs and regional medical
centers to implement a unified policy to address medica-
tion disposal in the short-term. In tandem, an effort
should be made to recruit the biotechnology sector in
high-tech and academia to develop new technologies in
medication design and water filtration to decrease expo-
sures in the long-term.
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